Cereno Scientific’s drug candidate CS585 published in top-tier journal Blood with favorable preclinical data on prevention of thrombosis
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that a publication concerning drug candidate CS585 has been published in the top peer-reviewed medical journal Blood. The publication shows that CS585, a prostacyclin receptor agonist, is a highly potent and selective compound given both orally and intravenously and prevents thrombosis for up to 48 hours as observed in preclinical studies.The publication titled “The oxylipin analogue CS585 prevents platelet activation and thrombosis through